Novo Nordisk’s new Wegovy semaglutide pill, used for obesity, faces FDA criticism for misleading advertisement claims. FDA letter requests immediate action to address violations, including ceasing misleading ads. Novo Nordisk confirms receipt of letter and plans to respond to FDA concerns. The pill is vital for Novo Nordisk to regain market share.

The FDA points out that Novo’s ad for the Wegovy pill implies superior benefits compared to other GLP-1 weight loss drugs, despite lack of evidence. The ad also fails to properly present risk information, a requirement for TV drug advertising. Novo Nordisk also sues telehealth company Hims & Hers to stop marketing compounded versions of Wegovy.

Read more at CNBC: FDA says Novo Nordisk’s obesity pill TV ad includes misleading claims